Engineering and Design of Chimeric Antigen Receptors

Abstract excerpt

T cells engineered with chimeric antigen receptors (CARs) have emerged as a potent new class of therapeutics for cancer, based on their remarkable potency in blood cancers. Since the first clinical reports of their efficacy emerged 7 years ago, investigators have focused on the mechanisms and properties that make CARs effective or toxic, and their effects on T cell biology. Novel CAR designs coupled with...

Topics

Join the communities discussing this publication.

• CAR-T cell therapy research
• Nanowire Synthesis and Applications